动脉内内皮抑制素联合化疗栓塞治疗原发性肝癌后血浆VEGF水平的动态观察

目的：探讨动脉内重组入血管内皮抑制素（recombinant human endostatin，rh-endostatin）及化疗栓塞（transarterial chemoembolization，TACE）治疗原发性肝癌（hepatocellular carcinoma，HCC）对血浆血管内皮生长因子（vascular endothelial growthfactor，VEGF）表达的动态变化。方法：40例临床诊断为HCC的患者，随机分成2组，各20例，分别用rh-endostatin加TACE术或单纯TACE术治疗，所有病例均于TACE术前、术后3、7d及1个月时抽血，用ELISA法定量检测血浆中VEGF的表达水平。结果：rh-endostatin加TACE术组HCC患者血浆中VEGF表达水平术后3d明显升高，与术前比较差异有统计学意义（P=0．019），术后7d、1个月血浆中VEGF表达水平下降至与术前比较差异无统计学意义（P=0．577及P=0．740）；单纯TACE术组HCC患者血浆VEGF表达水平在术后3d、术后7d逐渐升高，与术前比较差异有统计学意义（P=0．014及P=0．002），术后1个月血浆VEGF表达水平逐渐下降，与术前比较差异无统计学意义（P=0．710）。结论：通过动态检测2组HCC患者血浆VEGF的表达水平，反映了rh-endostatin对血浆VEGF表达的影响，间接说明rh-endostatin对肿瘤血管生成有一定的抑制作用。     

血清VEGF、bFGF与乳腺癌生物学行为的关系

目的：探讨VEGF、bFGF与乳腺癌的生物学行为的关系,复发转移患者血清VEGF、bFGF的表达水平与化疗疗效的关系。方法：应用ABC—ELISA方法检测乳腺癌患者血清VEGF、bFGF的表达情况。结果：术前未作放化疗的乳腺癌患者术前血清VEGF、bFGF表达水平明显高于健康体检者、乳腺腺瘤患者（P〈0．05）,也明显高于同组患者术后血清VEGF、bFGF表达水平（P〈0．05）。术前未作放化疗的乳腺癌患者术前血清VEGF、bFGF的表达水平与原发肿瘤的大小、TNM分期、淋巴结转移有关。术前未作放化疗的乳腺癌患者术前血清VEGF与bFGF的表达水平呈正相关（r=0．210,P〈0．05）。乳腺癌复发转移组化疗前血清VEGF、bF—GF的表达水平比健康体检者及无病生存组明显增高（P〈0．05）。乳腺癌复发转移组化疗后CR＋PR组血清VEGF、bFGF表达水平比化疗前明显减低（P〈0．05）;化疗后NC＋PD组血清VEGF、bFGF表达水平比化疗前略高,但没有显著性差异（P〉0．05）。乳腺癌复发转移组化疗后CR＋PR组血清VEGF、bFGF表达水平比NC＋PD组明显降低（P〈0．05）。结论：乳腺癌患者血清VEGF、bFGF的表达水平与乳腺癌生物学行为有关,而且与化疗疗效有关,提示通过检测乳腺癌患者血清VEGF、bFGF的表达水平可能对乳腺癌的诊断、客观预测肿瘤的复发转移、选择合理有效的治疗方案有一定的参考价值。     

血清VEGF在肝癌栓塞化疗时的变化对疗效影响的研究

目的 :探讨血清VEGF对肝癌栓塞化疗疗效的影响。方法 :分析 30例肝细胞肝癌患者的血管造影 ,并采用ELISA检测 2 0例TACE前后患者血清VEGF的变化。结果 :1 3例肿瘤富血管患者血清VEGF水平高于 1 7例肿瘤乏血管患者 (8 80± 3 2 3ng/mlvs 5 70± 2 .68ng/ml,P <0 0 5) ;患者肝动脉栓塞治疗前后血清VEGF分别为 7 41± 3 56ng/ml,8 72± 3 79ng/ml,P <0 0 5。有 1 6例患者血清VEGF水平在肝动脉栓塞治疗后升高 ,其中 1 2例在第二次血管造影时发现新生肿瘤血管 ,他们的血清VEGF水平显著升高达 1 0 84± 2 70ng/ml。血清VEGF浓度升高的患者介入的临床疗效较差。结论 :肝癌TACE后若肿瘤细胞表达VEGF增强 ,其预后差 ,血清VEGF是影响肝癌栓塞化疗效果的因素之一     

COX-2在原发性肝癌介入化疗后的表达变化及意义

目的：探讨肝癌介入化疗栓塞前后COX-2的表达变化及其临床意义。方法：肝癌患者随机分为两组，对照组12例采用对症支持治疗，治疗组12例采用经肝动脉化疗栓塞（TACE）治疗。对照组及治疗组治疗前及治疗后2周肝穿活检取得标本，免疫组织化学分析COX-2的表达，观察生存期。结果：COX-2蛋白在癌组织细胞内高表达，治疗组与对照组治疗前比较无差异（P〉0．05），治疗组TACE后表达增强（P〈0．05）；COX-2评分高的患者生存期较短，两者呈反曲线关系（P〉0．05）。结论：肝癌TACE后COX-2表达增强，COX-2可成为肿瘤预后指标及治疗靶向，选择特异性COX-2抑制剂可提高肝癌介入治疗的疗效。     

鼻咽癌患者放射治疗前后血清VEGF和bFGF的变化

[目的]探讨鼻咽癌（NPC）患者放射治疗前后外周血清血管内皮细胞生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）的变化。[方法]42例NPC患者作为放疗组予以放射治疗。40例健康体检者作为正常对照组。采用酶联免疫吸附试验（ELISA）检测放疗前后NPC患者外周血清VEGF和bFGF的含量，并与对照组比较。[结果]放疗前NPC患者血清VEGF和bFGF显著升高，与对照组比较有统计学意义（P〈0．01）。放疗后3个月NPC患者血清VEGF和bFGF明显下降，接近对照组水平（P〉0．05），放疗后1年复发者血清VEGF和bFGF水平持续异常（P〈0．01），未复发者血清VEGF和bFGF水平恢复正常（P〉0．05）。放疗前后患者血清VEGF和bFGF的浓度变化呈正相关（P=0．0011，r=0．7981）。[结论]NPC患者血清中VEGF和bFGF高表达，测定NPC患者血清中VEGF和bFGF的变化对临床疗效观察和预后判断均有重要的临床意义。     

血清血管内皮生长因子在肝癌介入栓塞后的表达

目的探讨血清血管内皮生长因子(VEGF)在肝癌栓塞化疗(TACE)后的表达水平和临床意义。方法分析63例肝细胞肝癌患者的血管造影结果和VEGF血清表达水平,采用ELISA法检测40例TACE前后患者血清VEGF的变化。结果 43例肿瘤富血管患者血清VEGF水平高于20例肿瘤乏血管患者[(136.80±52.13)pg/mlvs(62.30±31.17)pg/ml,P<0.05];患者肝动脉栓塞治疗前后血清VEGF分别为(87.41±43.16)pg/ml和(128.42±43.12)pg/ml,P<0.05.其中有36例患者血清VEGF水平在肝动脉栓塞治疗后升高,第二次血管造影发现27例新生肿瘤血管的患者血清VEGF水平显著升高(179.13±66.27)pg/ml。血清VEGF浓度明显升高的患者介入治疗疗效较差。结论肝癌TACE后肿瘤细胞表达VEGF增强,血清VEGF是影响肝癌栓塞化疗效果的因素之一。     

晚期非小细胞肺癌患者外周血VEGF和bFGF及MMP-9水平与预后的关系

目的 检测晚期非小细胞肺癌（NSCLC）患者化疗前后外周血血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）和基质金属蛋白酶-9（MMP-9）的水平,探讨其与疗效、预后的关系。方法 酶联免疫吸附试验（ELISA）检测46例晚期NSCLC患者化疗前后血浆VEGF、bFGF和MMP-9水平,并对随访资料进行生存分析,应用COX回归模型分析预后影响因素。结果 化疗前血浆VEGF、bFGF和MMP-9中位值分别为275pg／ml、69pg／ml和122ng／ml,均高于健康对照组（P〈0．05）。化疗前血浆VEGF与bFGF水平正相关,Spearman’S相关系数为0．329。化疗前血浆VEGF、bFGF和MMP-9水平与白细胞、血色素、血小板计数无相关性,与年龄、性别、病理类型、分化程度、TNM分期等亦无关。Ⅳ期广泛转移者（包括骨转移）化疗前血浆MMP-9水平显著高于仅有骨转移者（P=0．013）。化疗后血浆bFGF下降为预后的独立保护因素,RR=11．737（P=0．02）。结论 检测晚期NSCLC患者外周血的某些血管生成相关因子,可能有利于协助预测转移倾向及评价预后。     

三氧化二砷抑制小鼠H22肝癌移植瘤血管生长的实验研究

目的：探讨三氧化二砷（As2O3）对小鼠H22肝癌移植瘤组织血管生成的抑制作用。方法：建立小鼠H22肝癌移植瘤模型，腹腔应用As2O3治疗后，通过瘤体体积及瘤重的比较，病理观察血管分布，VEGF及bFGF免疫组化检测，反映As2O3对小鼠H22肝癌组织血管生成的抑制作用。结果：As2O3高剂量及低剂量组均有效地抑制荷瘤鼠皮下肿瘤的体积及瘤重，瘤重抑瘤率分别为39．32％、44．89％，病理观察发现As2O3治疗组的肿瘤血供较对照组明显减少，免疫组化检测结果为As2O3治疗组肿瘤细胞的VEGF阳性细胞数低于对照组VEGF阳性细胞数，As2O3治疗组bFGF阳性表达率明显低于对照组（P〈0．01），有显著差异。结论：As2O3对小鼠肝癌移植瘤血管生成具有明显的抑制作用，具有治疗肝癌的潜在价值。     

经肝动脉灌注重组人血管内皮抑制素联合TACE治疗兔VX 2肝癌及肿瘤血管生成的评估

目的：经肝动脉灌注重组人血管内皮抑制素（recombinant human endostatin，rh-endostatin）联合经导管动脉内化疗栓塞术（transcathet artefial chemoembolization，TACE）治疗兔VX2肝癌后，对其疗效进行评估，并分析肿瘤周边CT灌注特征及微血管密度（microvascular density，MVD）、血管内皮生长因子（vascular endothelial growth factor，VEGF）表达的变化，探讨CT灌注参数、MVD及VEGF之间的相关性。方法：30只VX2肝癌兔随机分为3组，每组10只。A组：rh-endostatin＋TACE；B组：单纯TACE；C组：对照组。3组于治疗前均行CT平扫，治疗后2周行CT灌注成像，获取肿瘤周边血流量（blood flow，BF），血容量（blood volume，BV）；毛细血管表面渗透面积（permeability surface area product，PS）值。扫描后立即处死动物，组织切片用于免疫组织化学法检测MVD、VEGF表达。结果：A、B组肝癌生长率均明显低于C组（P〈0．01）；A组肿瘤BF、BV、PS值较B、C组明显增高（P〈0．05），MVD、VEGF较B、C组明显减低（P〈0．01）。B、C组之间BF、BV、PS、MVD及VEGF差异均无统计学意义（P〉0．05）。在3组中，肿瘤VEGF与MVD之间均呈显著正相关（P〈0．01），A组中BF、BV、PS分别与MVD、VEGF呈线性正相关（P〈0．05），而B、C组中BF、BV、PS与MVD、VEGF无线性相关性（P〉0．05）。结论：肝动脉灌注rh-endostatin联合TACE治疗肝癌能减慢肿瘤的生长速度，显著地抑制治疗后肿瘤新生血管的形成。肿瘤CT灌注参数不总是能反映其病理参数MVD、VEGF的变化。     

动态监测血清VEGF在宫颈鳞癌化疗前后的变化

目的研究宫颈癌化疗前后血管内皮生长因子（vascular endothelial growth factor,VEGF）的改变,探讨VEGF能否作为评判化疗近期疗效的预测指标,为制定合理的治疗方案提供参考。方法采用酶联免疫吸附法（ELlSA）检测60例宫颈鳞癌患者及20例正常健康妇女血清中VEGF水平并进行对照分析。结果宫颈癌患者血清中VEGF水平显著高于正常健康妇女血清中VEGF水平（P〈0．01）,且宫颈癌Ⅰ期血清VEGF值低于Ⅱ期者（P〈0．05）;宫颈癌患者术后血清VEGF表达较术前明显上升（P〈0．01）,术后化疗后血清VEGF水平较术后明显下降（P〈0．01）;宫颈癌Ⅰ期患者术后化疗后血清VEGF水平与术前比较差异无统计学意义（P〉0．05）,宫颈癌Ⅱ。期、Ⅱ。期患者术后化疗后血清VEGF水平均低于术前（P〈0．05）;宫颈癌Ⅱ。期患者新辅助化疗（neoadjuvant chemotherapy,NACT）后血清VEGF浓度较NACT前降低（P〈0．05）。结论VEGF可作为预测宫颈癌化疗近期疗效和判断术后是否需要辅助化疗及化疗疗程数的参考指标。     

High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study

Vascular endothelial growth factor (VEGF) is an important mediator of tumor angiogenesis. A high serum VEGF level has been shown to predict poor response to chemotherapy and poor survival in several cancers, but its prognostic value in hepatocellular carcinoma (HCC) remains unknown. We conducted a prospective study to evaluate the prognostic significance of pretreatment serum VEGF levels on tumor response to treatment and survival of patients with HCC undergoing transarterial chemoembolization (TACE). Pretreatment serum VEGF levels were measured by an enzyme-linked immunosorbent assay in 80 patients with inoperable HCC undergoing TACE. Serum VEGF levels were correlated with clinical data, tumor response to TACE and survival results. The median serum VEGF level was 240 pg/ml (range 9-1730). Serum VEGF levels were positively correlated with the presence of venous tumor thrombus (P=0.011). Pretreatment serum VEGF levels were significantly higher in patients with progressive disease (median 434 pg/ml) than those with stable (median 176 pg/ml, P=0.010) or responsive disease (median 142 pg/ml, P<0.001) after TACE. Patients with serum VEGF >240 pg/ml had significantly worse survival than those with serum VEGF <240 pg/ml (median survival 6.8 vs. 19.2 months, P=0.007). In a Cox multivariate analysis, serum VEGF >240 pg/ml was an independent prognostic factor of survival. In conclusion, the results of this study suggest that serum VEGF level may be useful as a novel prognostic predictor of tumor response and survival of patients with inoperable HCC undergoing TACE treatment.     

Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have both been implicated to have roles in tumour angiogenesis. In the present retrospective study, serum VEGF and bFGF from patients with locally advanced non-small cell lung cancer (NSCLC) were analysed before, during and after treatment. Seventy-three patients and a total of 460 serum samples were analysed for VEGF and 443 serum samples were analysed for bFGF. Pre-treatment bFGF levels in patients with normal platelet counts, were correlated to poorer survival, P-value = 0.047. During chemotherapy, each rise of one unit bFGF corresponded to a hazard ratio of 4.06 (P=0.022). In patients with normal platelet counts, VEGF levels after radiotherapy significantly correlated to good prognosis (P=0.023), during radiotherapy VEGF levels indicated the same correlation (P=0.085). We conclude that serum VEGF and especially bFGF are of clinical interest as prognostic factors, especially in patients presenting with normal platelet counts.     

Serum endostatin levels are elevated in patients with soft tissue sarcoma

BACKGROUND: Solid tumors are angiogenesis dependent, and elevated levels of proangiogenic cytokines have been reported in a variety of histologies. Endostatin is an antiangiogenic fragment of the basement membrane protein, collagen XVIII. Because antiangiogenic protein fragments may be generated by tumor-derived proteases, the authors sought to determine whether circulating levels of endostatin were elevated in patients with localized soft tissue sarcoma. METHODS: The authors analyzed preoperative serum levels of endostatin, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) in 25 patients (14 males and 11 females; mean age, 44 years) with soft tissue sarcoma. For each serum sample, two aliquots were assayed in duplicate using a competitive enzyme immunoassay. Serum levels were compared with levels from 34 age-matched and gender-matched volunteer blood donors. RESULTS: Endostatin levels were significantly higher in sera from sarcoma patients than in sera from healthy controls (43.0 ng/mL vs. 25.8 ng/mL, respectively; P = 0.0002; Mann-Whitney U test). Significant elevations also were noted in VEGF and bFGF levels (P = 0.0002 and P = 0.0001, respectively). Furthermore, endostatin levels > 2 standard deviations above the control mean (55 ng/mL) were associated with an increased risk of tumor recurrence after resection (P = 0.047; log-rank test). CONCLUSIONS: Serum endostatin, VEGF, and bFGF levels are elevated in patients with soft tissue sarcoma. Elevated endostatin levels appear to be associated with tumor aggressiveness. The role of these cytokines in sarcoma angiogenesis and as potential targets for therapy warrants further study.     

TACE联合血管内皮抑制素治疗肝癌的短期疗效及其对患者血清VEGF、MMP-9、OPN的影响

目的:探讨经肝动脉化疗栓塞（TACE）联合血管内皮抑制素治疗肝癌的短期疗效及其对患者血清VEGF、MMP-9、OPN的影响。方法:选取2012年4月-2013年4月我院收治的原发性肝细胞癌（简称肝癌）患者80例,按照随机对照法分为观察组和对照组各40例,其中观察组给予TACE联合重组人血管内皮抑制素（恩度）治疗,对照组采用单纯的TACE治疗,观察两组患者治疗前、治疗后1、3、7、15、30d血清血管内皮生长因子（VEGF）、基质金属蛋白酶9（MMP-9）、骨桥蛋白（OPN）水平的变化,观察两组患者肿瘤新生血管抑制情况、肿瘤控制情况及1年生存率。结果:治疗前两组的血清VEGF、MMP-9、OPN水平比较差异无统计学意义（P＞0.05）;治疗后各时间节点观察组血清VEGF、MMP-9、OPN水平与治疗前比较差异无统计学意义（P＞0.05）;而对照组治疗后各时间节点血清VEGF、MMP-9、OPN水平均较治疗前明显升高,差异具有统计学意义（P＜0.05）;观察组患者新生血管控制率、疾病控制率（DCR）及术后1年生存率均明显优于对照组,差异具有统计学意义（P＜0.05）。两组的不良反应发生率比较差异无统计学意义（P＞0.05）。结论:TACE联合血管内皮抑制素治疗肝癌可以有效抑制肿瘤新生血管的形成,降低肿瘤复发转移的几率,延长患者的生存时间,提高生存率,其作用机制可能与抑制TACE术后血浆VEGF、MMP-9、OPN水平有关。     

短期给予生长抑素抑制胃癌血管形成的研究

背景与目的:抑制恶性肿瘤的血管形成是目前肿瘤治疗研究的热点之一,本试验旨在探讨皮下注射生长抑素类似物对胃癌血管形成的抑制作用。方法:通过术前胃镜取材及免疫组织化学染色筛选血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)和生长抑素受体2(somatostatinreceptor2,SSTR2)表达阳性的25例胃癌患者纳入本研究。给予善得定10μg/kg皮下注射,每日两次共7天,然后行手术治疗。通过ELISA法检测用药前和用药后第1、3、7天血清VEGF和碱性成纤维细胞生长因子(b-fibroblastgrowthfactor,bFGF)的浓度,应用Westernblot法检测手术前后肿瘤组织VEGF和bFGF的表达。免疫组织化学染色检测手术前后肿瘤微血管密度的变化。结果:用药1周后血清VEGF浓度较用药前显著下降犤(1.02±0.41)μg/Lvs(1.88±0.87)μg/L,P<0.05犦,血清bFGF浓度较用药前显著下降(0.88±0.32)ng/Lvs(2.12±1.06)ng/L,P<0.05;用药后组织VEGF表达显著下降犤(吸光度值:1306vs488,P<0.01)犦,bFGF表达也显著下降(吸光度值:1287vs512,P<0.01)。用药后肿瘤微血管密度有降低趋势,但两者间差异无统计学意义(P>0.05)。结论:短期给予生长抑素可以降低胃癌组织中VEGF和bFGF表达,但对微血管密度的影响无统计学意义。用药后血清VEGF和bFGF浓度随治疗时间     

Serum endostatin predicts tumor vascularity in hepatocellular carcinoma

BACKGROUND: Tumor angiogenesis is a strong prognostic factor in patients with hepatocellular carcinoma (HCC). However, to the authors' knowledge, details regarding the serum levels of proangiogenic and antiangiogenic growth factors controlling this process are not yet known. METHODS: Serum endostatin, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) levels were measured by the enzyme immunoassay method in prospectively collected samples from 33 HCC patients who had received no preoperative therapy. The angiogenic score (AS) and endostatin localization were evaluated using immunohistochemistry. RESULTS: Significant decreases in serum endostatin (P = 0.0007) and bFGF (P = 0.0004) were observed in postoperative samples compared with the preoperative values. A very strong direct correlation was noted between VEGF and endostatin (P < 0.0001). Only the preoperative serum endostatin was found to have a significant (P = 0.0025) inverse correlation with the AS. Furthermore, the combined positivity for bFGF and VEGF and negativity for endostatin was found to have a significantly (P = 0.0069) positive correlation with AS. Significantly high levels of endostatin were noted in patients with trabecular-type tumors (P = 0.0446) and in patients with hepatitis B infection (P = 0.0183). The serum endostatin level was found to be significantly (P = 0.0166) higher in living patients and patients with high serum endostatin levels had a tendency (P = 0.0871) toward long survival. Tissue endostatin expression was found to have a direct correlation with the serum endostatin level (P = 0.0117). CONCLUSIONS: The measurement of serum endostatin can predict tumor vascularity and may serve as a promising tool in the antiangiogenic therapy for patients with HCC.     

肝细胞癌介入栓塞前后血管内皮生长因子和内皮抑素的变化与预后的关系

目的 探讨肝细胞癌患者肝动脉化疗栓塞术(TACE)前后血管内皮生长因子(VEGF)和内皮抑素(ES)变化规律与预后的关系.方法 酶联免疫吸附试验(ELISA)法检测患者TACE术前及术后1周血清VEGF和ES水平.结果 肿瘤直径≥5 cm的患者,ES在治疗前后分别为(43.35±9.80)ng/ml、(48.35±10.89)ng/ml;VEGF分别为(310.23±64.31)ng/ml、(369.10±60.11)ng/ml.肿瘤伴有门静脉癌栓的患者ES在治疗前后分别为(54.28±8.78)ng/ml、(50.28±7.51)ng/ml;VEGF分别为(331.26±63.38)ng/ml、(400.29±60.98)ng/ml.VEGF和ES水平与肿瘤大小、门静脉癌栓以及临床分期密切相关(P＜0.05).肝细胞癌患者临床分期越晚,TACE前、后VEGF和ES水平均越高.晚期肝癌患者VEGF/ES比值明显高于早期患者.VEGF/ES比值越低生存时间越长.结论 VEGF、ES、VEGF/ES比值可作为预测肝细胞癌治疗效果的指标.     

乳腺癌组织和血清中内皮细胞抑制素VEGF表达与肿瘤血管生成

目的:研究乳腺癌患者癌组织和血清内皮细胞抑制素(ES)、VEGF表达和肿瘤血管生成间的关系,初步探讨乳腺癌血管生成调节机制.方法:采用免疫组化法检测59例乳腺癌组织ES、VEGF表达及其微血管密度(MVC);分别采用竞争性酶联免疫试验和ELISA测定患者乳腺癌组织和手术前、后血清ES及VEGF水平.结果:1)癌组织ES、VEGF阳性表达率分别为69.5%和59.3%,明显高于癌旁组织(P＜0.005).2)手术前乳腺癌组血清ES和VEGF水平显著增高;手术3周后,血清VEGF水平明显下降,而ES仍保持在较高水平.3)癌组织VEGF表达、组织和血清VEGF水平间具有密切相关性(P＜0.05);癌组织ES表达和血清ES水平间仅有弱的关联(P=0.06).4)癌组织VEGF阳性和阴性组,MVC分别为37.5±10.3和22.8±8.3,有显著性差异(P＜0.001),且血清VEGF浓度与MVC呈正相关(P＜0.0001,r=0.63);癌组织VEGF表达阴性组,血清ES与MVC显示负相关(P=0.03,r=-0.45).结论:VEGF是促进乳腺癌血管生成的直接相关因子,而ES可能是肿瘤及其转移的血管生成负调控因子.     

Quantification of angiogenesis stimulators in children with solid malignancies

Humoral angiogenesis stimulators including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have been implicated in the pathogenesis of solid malignancies. However, it has remained unclear whether both stimulators contribute to the development and progression of solid malignancies of children. The aim of the present study was to determine whether VEGF and bFGF are elevated in body fluids of children with solid malignancies and, if so, whether these elevated levels correlate with clinical parameters. Using enzyme-linked immunosorbent assays (ELISAs), we quantified VEGF and bFGF in serum (n = 107) and urine (n = 57) of healthy children and of children with solid malignancies (serum: n(VEGF) = 69, n(bFGF) = 60; urine: n(VEGF) or n(bFGF) = 13). Finally, we compared patients' pre-therapeutic and post-therapeutic levels. Serum VEGF was elevated in children with several solid tumors (Ewing's sarcoma, primitive neuroectodermal tumours, malignant lymphoma, Langerhans cell histiocytosis and medulloblastoma). In contrast, serum bFGF, urinary bFGF or urinary VEGF were not significantly elevated. Upon successful therapy, elevated pre-therapeutic serum VEGF levels declined to levels present in healthy children. VEGF could contribute to the progression of pediatric solid malignancies, and serum VEGF could be used to monitor therapeutic response. Furthermore, the determination of angiogenesis stimulators could identify patients eligible for anti-angiogenic therapy.     

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.

PURPOSE: To determine the predictive value of the angiogenic serum factors angiogenin, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and interleukin-8 (IL-8) for the prognosis of patients with malignant melanoma. PATIENTS AND METHODS: Angiogenin, VEGF, bFGF, and IL-8 were measured in sera of 125 melanoma patients with different stages of disease and with or without current therapy including interferon alfa and different cytostatics in comparison with 30 healthy controls using enzyme-linked immunosorbent assay. RESULTS: Serum levels of angiogenin, VEGF, bFGF, and IL-8 were significantly increased in melanoma patients compared with healthy controls. Elevated serum concentrations of VEGF, bFGF, and IL-8 were associated with advanced disease stages and tumor burden. Cytostatic therapy of patients was accompanied by increased serum levels of angiogenin, bFGF, and IL-8. As shown by univariate analysis, elevated serum levels of VEGF (P = .0001 and .0036), bFGF (P < .00005 and < .00005), and IL-8 (P < .00005 and < .00005) were strongly correlated with a poor overall and progression-free survival, respectively. Multivariate analysis revealed stage of disease (P = .0238), tumor burden (P = .0347), VEGF (P = .0036), bFGF (P = .0252), and IL-8 (P = .0447) as independent predictive factors of overall survival. Tumor burden (P = .0081), VEGF (P = .0245), and IL-8 (P = .0089) were found as independent predictive factors of progression-free survival. CONCLUSION: Our data suggest that the angiogenic serum factors VEGF, bFGF, and IL-8 are useful predictive markers for overall and progression-free survival in melanoma patients.